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Abstract. Radiotherapy is the standard treatment for head 
and neck squamous cell carcinoma (HNSCC), however, 
radioresistance remains a major clinical problem despite 
significant improvements in treatment protocols. Therapeutic 
outcome could potentially be improved if a patient's tumour 
response to irradiation could be predicted ex vivo before 
clinical application. The present study employed a bespoke 
microfluidic device to maintain HNSCC tissue whilst 
subjecting it to external beam irradiation and measured 
the responses using a panel of cell death and proliferation 
markers. HNSCC biopsies from five newly-presenting 
patients [2 lymph node (LN); 3 primary tumour (PT)] were 
divided into parallel microfluidic devices and replicates 
of each tumour were subjected to single-dose irradiation 
(0, 5, 10, 15 and 20 Gy). Lactate dehydrogenase (LDH) 
release was measured and tissue sections were stained for 
cytokeratin (CK), cleaved-CK18 (cCK18), phosphorylated-
H2AX (γH2AX) and Ki-67 by immunohistochemistry. In 
addition, fragmented DNA was detected using terminal 
deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL). Compared with non-irradiated controls, higher 
irradiation doses resulted in elevated CK18-labelling index 
in two lymph nodes [15 Gy; 34.8% on LN1 and 31.7% on 
LN2 (p=0.006)] and a single laryngeal primary tumour 
(20 Gy; 31.5%; p=0.014). Significantly higher levels of 
DNA fragmentation were also detected in both lymph node 
samples and one primary tumour but at varying doses of 
irradiation, i.e., LN1 (20 Gy; 27.6%; p=0.047), LN2 (15 Gy; 
15.3%; p=0.038) and PT3 (10 Gy; 35.2%; p=0.01). The 
γH2AX expression was raised but not significantly in the 
majority of samples. The percentage of Ki-67 positive nuclei 
reduced dose-dependently following irradiation. In contrast 
no significant difference in LDH release was observed 
between irradiated groups and controls. There is clear inter- 
and intra-patient variability in response to irradiation when 
measuring a variety of parameters, which offers the potential 
for the approach to provide clinically valuable information.
Introduction
World-wide head and neck cancer accounts for ~550,000 
new cases annually with ~290,000 deaths (1). Over the past 
five decades, a considerable amount of effort has been made to 
improve the treatment of patients with head and neck squamous 
cell carcinoma (HNSCC), be it surgery (2), chemotherapy (3), 
radiotherapy (4), non-surgical checkpoint-inhibition immuno-
therapy (5,6) or a combination of these (7). Radiotherapy is the 
primary treatment for early-stage laryngeal cancer (T1 and T2) 
and is commonly used in conjunction with chemotherapy in 
T3 laryngeal and oropharyngeal squamous cell carcinoma 
patients. However, despite the improvements in treatment 
modalities, the overall 5-year survival rate for patients with 
head and neck cancer remains low, achieving only 66% for 
oral cavity cancers and 63% for cancers of the pharynx and 
larynx (8), which is thought to be largely due to the recur-
rence of the primary tumour as well as intrinsic tumour 
radioresistance (9-11). Still, what is lacking is a comprehensive 
understanding of the biological mechanisms of radiotherapy 
sensitivity, resistance and associated biomarkers. Numerous 
studies have focused on the identification of predictive 
biomarkers for radioresistance by studying biopsies removed 
from treated patients (12-16). In contrast, only a few studies 
have taken pieces of the actual patient tumour and subjected 
them to in vitro irradiation with the aim of predicting patient 
specific tumour sensitivity (17,18), due to the inability to 
maintain the tumour tissue ex vivo. The evaluation of tumour 
responses to irradiation ex vivo prior to commencement of the 
therapeutic intervention, would mean that treatment regimens 
could be designed on a rational rather than an empirical basis, 
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leading to improved quality of life with less side-effects and 
associated morbidity.
Microfluidic devices provide a platform on which a biomi-
metic microenvironment for human tissues can be maintained, 
allowing the culture of biopsies under pseudo in vivo condi-
tions (19). These are simple, reproducible, and highly versatile 
systems for tissue culture with the preservation of 3-dimen-
sional architecture (20). Microfluidic-based tissue culture 
mimics the systems of the human body with continuous 
perfusion, permitting the constant supply of nutrients to, and 
removal of waste from, multiple pieces of the same patient 
tissue in parallel (21).
Microfluidic culture of head and neck tumour tissue has 
been demonstrated previously by colleagues, in which the 
viability of the cultured tissues was confirmed by the relatively 
low release of cytosolic enzymes (LDH and cytochrome c) and 
high release of proliferation markers (metabolised tetrazolium 
salts) (18,22-24). A report by Carr et al (18) is the only study 
so far investigating the response of HNSCC to on-chip X-ray 
irradiation and showed that administration of fractionated 
irradiation doses (5x2 Gy over a 5-day period) demonstrated 
an enhanced level of apoptotic cell death compared to non-irra-
diated control tissue based on the increased expression of 
caspase-cleaved cytokeratin 18 (cCK18); also the study showed 
increased LDH release following high doses of irradiation.
DNA repair pathways remove radiation-induced DNA 
lesions and protect tumour cells from death. The evidence for 
the radio-protective effect of cellular DNA repair has been 
confirmed in cellular, animal and human studies (25-27); 
individuals with defects in DNA repair pathways often display 
hypersensitivity to radiation (28,29). Building on the results 
of previous studies, the present study aimed to determine the 
effects of single-dose external beam irradiation on microflu-
idic-perfused HNSCC biopsies using an extended panel of 
biological markers and expression profiles: caspase-dependent 
apoptosis (cCK18), caspase-independent necrotic cell death 
(LDH), DNA damage repair (phosphorylated H2AX), DNA 
fragmentation (TUNEL) and proliferative status (Ki-67). 
Ultimately it is hoped that these data could be used to 
customise patient treatment on a rational basis.
Materials and methods
HNSCC tissue collection. Samples of HNSCC primary or 
metastatic node tissue were obtained from 5 patients under-
going resection surgery at Castle Hill Hospital (Hull, UK) 
with no history of previous treatment (Table I). The project 
had approval from the Local Research Ethics Committee 
(LREC-10/H1304/6) and Hull and East Yorkshire NHS Trust 
R&D (R0987), and all patients provided written, informed 
consent. Tissue samples were transported to the laboratory in 
complete Dulbecco's modified Eagle's medium [DMEM; supple-
mented with 10% (v/v) foetal bovine serum (fBS); Biosera, 
East Sussex, UK), 100 U/ml penicillin, 100 µg/ml streptomycin, 
2 mM (v/v) L-glutamine and 2.5 µg/ml fungizone (Thermo 
Fisher, Paisley, UK)] and snap-frozen in liquid nitrogen before 
storage at -80˚C prior to microfluidic culture.
Incubation of HNSCC tissue in a microfluidic device. The 
microfluidic devices were manufactured in-house in the 
Department of Chemistry (University of Hull) and consisted 
of two thermally bonded layers of glass with micro-etched 
channels as described previously [(18,22); fig. 1A)]. As the 
etching process occurs both horizontally as well as vertically 
it creates channels with a trapezoidal cross-section (30).
A piece of HNSCC tissue (5-10 mg) was placed in the central 
tissue chamber (fig. 1) and perfused with complete DMEM 
(supplemented with 30 mM HEPES and 0.1 mM NEAA; all 
medium and supplements were from PAA, Somerset, UK, unless 
otherwise stated) using tubing connected to a syringe mounted 
in a Harvard PhD 2000 syringe pump (Harvard, Kent, UK), 
delivering medium at a rate of 2 µl/min. The microfluidic device 
was placed in a 37˚C incubator (Novital, Italy; fig. 1B) and the 
effluent was collected at 2-h intervals and overnight before 
storage for up to 6 days at 4˚C for analysis of LDH content.
The fluid flow pattern in the microfluidic device was 
laminar with a flow velocity of 3.96x10-3 m/sec and a Reynolds 
number within the microchannel of 0.386. Diffusion becomes 
a crucial transport mechanism between the fluid flow and 
tissue, thus allowing the tissue to access nutrients and reagents 
supplied via culture medium as well as disposing of cellular 
waste. This system mimics the nutrient exchange between 
capillaries and tissue in vivo. when the culture medium is 
perfused into the microchannel, the fluid layer near the channel 
is renewed rapidly while the liquid within the chamber mostly 
recirculates (31). The nutrients from the channels gradually 
diffuse into the chamber while the waste products diffuse out 
from the chamber.
In vitro irradiation of tissue in a microfluidic device. 
Ten parallel microfluidic devices perfusing HNSCC tissue from 
the same patient were set up each time and following 24 h of 
incubation were subjected to single-dose irradiation in duplicate 
(0, 5, 10, 15 and 20 Gy). Irradiation was applied to the tissue 
under the guidance of medical radiation physicists, using a 
6Mv X-ray beam from a varian Clinical Linear Accelerator. 
During irradiation, the microfluidic device was housed inside a 
perspex block which served as a surrogate for the tissue around 
the tumour (fig. 1C). At a dose rate of 600 MU/min, computer-
ised tomography planning calculated that each beam delivered 
53 mU, producing a dose of 1 Gy to the centre of the tissue at 
gantry angles of 90˚ and 270˚ with an 8x8 cm field. following a 
further 24 h of culture post-irradiation, tissue was embedded in 
OCT embedding medium (CellPath Ltd., UK) and snap-frozen 
in liquid nitrogen-cooled 2-methyl-butane (Sigma, UK) prior to 
cryosectioning for IHC analysis.
Measurement of lactate dehydrogenase (LDH). The release 
of LDH was measured using the LDH Cytotoxicity Kitplus 
(Roche Diagnostics, Hertfordshire, UK) according to the 
manufacturer's instructions. Medium alone values were 
subtracted from experimental readings before normalising by 
the weight of tissue to give LDH released/mg. values were 
grouped according to a 4-h interval to give a mean before and 
after irradiation.
Immunohistochemistry (IHC). Tissue sections (8 µm) were cut 
using a cryotome (Leica Cm 1100) and mounted onto StarFrost® 
glass slides (SLS, Nottingham, UK). IHC staining was carried 
out as described previously (18). The primary antibodies used 
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in the present study were monoclonal primary mouse anti-
human antibodies [m30 (cCK18; Peviva, Tewkesbury, UK), 
CK (Clone MNf116; Dako, Denmark), phosphorylated H2AX 
(Clone 2F3; γH2AX; BioLegend, UK) and Ki-67; (Clone 
MIB-1; Dako)] at a 1:100 dilution for 1 h at room temperature. 
matched isotype control antibodies at the same concentration 
provided a non-specific binding control. Antibody binding 
was detected with biotinylated horse anti-mouse secondary 
figure 1. Microfluidic set up for on-chip tissue irradiation. (A) Photograph and schematic diagram showing the assembly of the microfluidic glass device with 
inlet and outlet tubing and the cross-sectional illustration of microchannel. (B) Schematic diagram of the entire microfluidic culture set up and analyses. The 
medium-filled syringe was connected to the microfluidic device which was housed in a 37˚C incubator. (C) Irradiation of HNSCC tissue in the microfluidic 
device inside a custom made Perspex Block (160 mm width, 120 mm height, and 120 mm depth). The sample was irradiated isocentrically using a dose rate of 
600 MU/min using laterally opposing 8x8 cm fields with gantry angles of 90˚ and 270 .̊ Computerised tomography scans of the equipment were used to perform 
a 3D treatment planning calculation to produce a dose of 1 Gy at the sample, requiring 53 MU per field.
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antibody and an avidin/biotin system linked to horse peroxidase 
(vector Laboratories Ltd., Peterborough, UK), and subsequent 
reaction with 3, 3'-diaminobenzidine (DAB; Sigma). Sections 
were counterstained with Harris haematoxylin (Sigma), 
dehydrated through graded ethanols (70, 90 and 100%), and 
three changes of Histoclear, before mounting with Histomount 
(National Diagnostics, Hessle, UK).
Terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL). To detect DNA fragmentation, 8 µm 
tissue sections were fixed in 4% (w/v) paraformaldehyde for 
20 min before being washed with phosphate-buffered saline 
(PBS; pH 7.4) for 30 min (32). The cells were permeabilised 
(0.1% Triton X-100 and 0.1% sodium citrate), rinsed twice 
with PBS and incubated with terminal deoxynucleotidyl trans-
ferase (TdT) and TUNEL label reagent containing fluorescent 
dUTP, according to the manufacturer's instructions (Roche 
Diagnostics) for an hour in a dark humidified box at 37˚C. The 
tissue sections were rinsed three times with PBS before being 
mounted with vectashield® mounting medium containing 
4', 6-diamidino-2-phenylindole (DAPI; vector Laboratories 
Ltd). Additional tissue sections were subjected to 3,000 U/l 
DNase (Roche Diagnostics) treatment prior to TdT incuba-
tion to serve as a positive control while sections that were not 
exposed to TdT enzyme after DNase treatment served as a 
negative control.
Quantification and statistical analysis. A tiled image of the 
whole tumour section was constructed under x100 magnifica-
tion and positive staining for m30 and CK on serial sections was 
evaluated using Image Pro-premier software (Digital Imaging 
Systems; v9; fig. 2A). The labelling index of cCK18 was 
determined as the apoptotic area (m30 positive staining) over 
the total area of tumour cells (CK positive staining). γH2AX, 
TUNEL and Ki-67 were evaluated using five randomly selected 
tumour fields of x400 magnification (fig. 2B). The number 
of positively stained nuclei (γH2AX and Ki-67) and total 
nuclei in each field were counted manually using the Point or 
Multi-point function of ImageJ 1.48v (Java 1.6.0_20 64-bit) and 
the percentage positivity determined. The area of fITC (green; 
DNA fragmentation) staining over nuclear DAPI area (blue) on 
each x400 magnification field was determined and the mean 
percentage of five fields obtained (fig. 2B). The mean percentage 
of duplicate tissues at each irradiation dose were obtained and 
statistical differences between non-irradiated control and irradi-
ated tissues were determined using one-way ANOvA followed 
by Tukey's multiple comparison test (IBM SPSS Statistics 22).
Results
The effect of irradiation on the release of LDH. An initial 
high release of LDH was observed within the first 4 h  after 
experimental set-up in all tissues (fig. 3), after which, LDH 
release decreased and remained low in control tissues. 
Unexpectedly, the same was true for both the metastatic node 
and the tumour tissues subjected to irradiation, except for the 
primary tumours receiving a 5 Gy irradiation. In the 5 Gy 
treated biopsies, the LDH release increased by 45.5% during 
the first 4-h after irradiation and decreased to values similar 
to that of the control thereafter (fig. 3B).
The effect of irradiation on γH2AX expression. Clear positive 
brown nuclear staining of γH2AX, but not individual foci, 
was detected in the HNSCC tissue (fig. 4A) and irradiation 
of the two lymph node tissues (LN1 and 2) resulted in up 
to twice as many positive γH2AX cells compared with the 
control at both 10 and 15 Gy, however, the increase was not 
significant (fig. 5A). Irradiation of primary tumours 1 and 
3 also induced an increase in γH2AX expression at some 
irradiation doses, but again, these were not statistically 
significant. Despite demonstrating almost twice the basal 
level of γH2AX expression in the control compared with the 
other primary tumour tissues, PT2 demonstrated a significant 
dose-dependent increase in γH2AX expression following 
Table I. Clinicopathological details of five HNSCC patients, clinical treatment received and outcome.
Sample Subsite Stage Age; gender Therapy received Treatment outcome
    and datea (updated June 2016)
LN 1 Unknown TxN2am0 61; m Surgery and CRT No local or
 primary    regional recurrence
LN 2 Laryngeal T4N2bm0 58; m Surgery and CRT No information
 primary
PT 1 Oral cavity floor T3N0M0 49; M Surgery Passed away due to
 of mouth I    alcoholic liver disease
PT 2 Oral cavity floor T2N0 64; M Surgery No evidence of recurrence
 of mouth II
PT 3 Laryngeal  T2N0m0 68; F RT No evidence of loco-regional  
 supraglottis    recurrence
LN, lymph node; PT, primary tumour; CRT, chemoradiotherapy; RT, radiotherapy. aThe therapy details administered on these patients, including 
the doses and the chemotherapy drugs, were not available.
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treatment with 10, 15 and 20 Gy irradiation (p=0.022; 
p=0.020; p=0.003, respectively), reaching almost three times 
the percentage of positive nuclei at the 20 Gy dose (23.3±3.0% 
control vs. 66.0±8.0% 20 Gy).
The effect of irradiation on CK18-LI. Immunostaining with 
the m30 antibody demonstrated apoptotic cells with brown 
cytoplasm (fig. 4B). A dose of 15 Gy induced an elevated 
CK18-LI in LN1 (34.8±17.4%) and LN2 (31.7±4.9%) compared 
with the corresponding controls (11.4±4.0 and 7.9±2.1%, 
respectively; fig. 5B), but the difference was only significant 
in LN2 (p<0.05). The non-irradiated PT3 sample had greater 
apoptotic cell death (17.7±1.3%) compared with the corre-
sponding controls in other primary tumours (5.2±2.2% PT1; 
1.9±0.8% PT2) and irradiation induced a dose-dependent 
increase in apoptosis >10 Gy, however, the difference between 
irradiated tissue and controls was only significant following 
20 Gy irradiation (31.5±7.0% vs. control 17.7±1.3%; p=0.014). 
No significant increases in CK18-LI were observed for PT1 or 
PT2 following irradiation.
The effect of irradiation on DNA fragmentation. Green 
fluorescent nuclei demonstrated the presence of incorporated 
dUTP in apoptotic cells (fig. 4C). Insufficient tissue meant that 
figure 2. Image analyses on serially sectioned tissue using different markers. (A) IHC staining of (a) CK and (b) cleaved-CK18 (M30) on serially sec-
tioned lymph node tissue containing tumour metastases incubated in the microfluidic device with 5 Gy irradiation treatment (x100 magnification, tiled). 
(B) Representative image of same lymph node with tumour metastasis visualised at the same area at x400 magnification: (a) TUNEL assay and IHC staining 
of (b) γH2AX and (c) Ki-67.
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the evaluation of cells positive for DNA fragmentation in PT1 
samples was not possible. The basal fraction of cells demon-
strating fragmented DNA was <10% in all control tissues 
investigated, and this increased by >2-fold in the four tumours 
after irradiation, but this increase was not consistent across all 
doses and only significant following 20 Gy irradiation of LN1 
(27.6±10.2%), 15 Gy irradiation of LN2 (15.3±9.0%) and 10 Gy 
irradiation of PT3 (35.2±2.3%).
The effect of irradiation on proliferation. Positive brown 
nuclei, representative of Ki-67 positivity, were observed in 
controls as well as 5 Gy irradiated tissues (fig. 4D). Although 
the percentage of cells positive for the proliferation marker 
Ki-67 decreased in a dose-dependent manner in both meta-
static nodal tissues, the decrease was not significant compared 
to the controls (fig. 5D). The degree of proliferation in PT3 
decreased by approximately 5-fold following all irradiation 
doses except 15 Gy but the decrease was again not significant. 
In both the floor of mouth tumours (PT1 and PT2), the basal 
level of proliferation was <10% making any effects of irradia-
tion difficult to observe.
Comparison between in vitro results and clinical outcome. In 
order to determine whether the microfluidic culture of HNSCC 
tissue and its subsequent irradiation can predict whether a 
tumour is radioresistant/responsive, the data obtained in vitro 
figure 3. LDH release levels throughout tissue maintenance in microfluidic devices. Mean absorbance values of the tetrazolium product per mg tissue 
indicating LDH release at 4-h intervals throughout the incubation of tissue in microfluidic devices. (A) LDH released from lymph neck node metastases (n=2; 
metastasised from an unknown primary and a laryngeal primary tumour). (B) LDH released from primary tumours (n=3; two oral cavity floor of mouth 
tumours and a laryngeal supraglottic tumour). The tissues were subjected to microfluidic culture (0 Gy) and with four single-dose irradiations (5, 10, 15 and 
20 Gy). Solid-coloured bars indicate LDH released before irradiation, hatched bars show levels after irradiation. Arrows indicate the time of bilateral X-ray 
irradiation. Mean ± SEM.
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was compared with the in vivo response to irradiation (Table I). 
The samples were collected between April and August 2013 
with a minimum 2.5-year follow-up. At follow-up, no clinical 
information was recorded for LN2 and three of the remaining 
four patients were alive with no evidence of loco-regional 
recurrence (LN1, PT2 and PT3), however, only two of these 
figure 4. Representative staining images of serially cut tissue sections. Representative images of (A) γH2AX, (B) M30, (C) TUNEL and (D) Ki-67 on lymph 
neck node metastases following microfluidic culture (0 Gy) and four single-dose irradiations (5, 10, 15 and 20 Gy; x100 and x400 magnification).
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patients (LN1 and PT3) received any form of radiotherapy. 
The patient with a laryngeal supraglottic tumour (PT3; 
T2 tumour) who was treated clinically with radiotherapy 
had a positive outcome after 3 years with no loco-regional 
recurrence diagnosed, this is in agreement with the in vitro 
results which showed a positive response to irradiation in 
terms of increased cell death (both CK18-LI and TUNEL). 
LN1 received chemoradiotherapy with a positive outcome 
which was again reflected in the increased cell death levels 
(TUNEL) and a trend towards reduced proliferation (Ki-67) 
observed following on-chip irradiation.
Discussion
The biological mechanisms present in malignant cells which 
confer resistance to ionising radiation are largely unknown. The 
use of immortalised cell lines to investigate these mechanisms, 
although a good starting point, are not truly representative 
of the original in vivo tumours in terms of architectural and 
cellular complexity (33,34). The use of patient-derived xeno-
graft models offers the benefit of more closely reproducing 
the human in vivo tumour microenvironment for various 
therapeutic testing purposes. However, the process is lengthy 
figure 5. Tumour response of five HNSCC with increasing doses of irradiation. The tumour response was evaluated based on the expression of (A) γH2AX, 
(B) CK18-LI, (C) TUNEL and (D) Ki-67. Mean ± SEM. y-axis indicates the percentage of expression. Horizontal lines indicate the significant results between 
treated samples (5, 10, 15 and 20 Gy) and the non-irradiated control (0 Gy) based on one-way ANOvA with post hoc Tukey's test (p<0.05). At least two tissues 
were subjected to each treatment (n=2) and the number of repeats, if more than two is shown in parentheses. TUNEL results on PT1 were not possible due to 
the limitation of tissue.
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(xenograft generation takes up to six months), costly (tens 
of thousands of dollars), uses a large number of animals and 
the tumour is not entirely free from the rodent host influ-
ences (35-40). Microfluidic culture of 3-dimensional pieces of 
patient-derived tumour tissue (3 mm3) in a pseudo in vivo micro-
environment, has the potential to overcome many, if not all, of 
the limitations described above (41). The continuous delivery 
of nutrients and removal of waste from a piece of tissue whilst 
maintaining complex multicellular architecture, without rodent 
influence, gives microfluidic technology unique characteristics 
to be a platform for preclinical biological investigations. The 
ability to run multiple samples in parallel microfluidic devices 
is fundamental, to ensure representative parts of the tumour 
are responding in the same way to the treatment supplied, if 
this methodology is to be transferred into the clinical setting, 
whereas the development of multiple xenograft models for 
single regimen testing is much more difficult (37,39).
The present study has demonstrated the novel application 
of an in-house designed microfluidic device to interrogate the 
response of HNSCC tissues to irradiation, in terms of cell 
death and proliferation. Tumour perfusion and irradiation 
were carried out on chip, mimicking the microenvironment 
in vivo, whilst analysis of the markers was done either from 
the effluent collected during the perfusion, or using the tissue 
biopsies post-experiment. An initial peak of LDH release was 
observed at the beginning of the perfusion which is consistent 
with previous studies (18,22,23) and is most probably a result 
of cell damage caused during tissue manipulation. Previous 
studies which have used the same microfluidic device have 
measured increased LDH release from tissues in response to 
the addition of lysis buffer (23), when oxygen was removed 
from the culture medium (24), and following exposure to 
ethanol levels >100 mm (22), which helps to verify the 
viability of tissue prior to induction of damage. Elevated LDH 
serum levels in patients with nasopharyngeal carcinoma have 
also been detected in vivo following treatment with intensity-
modulated radiotherapy (42). In contrast, during the present 
study, the four single-dose irradiations ≤20 Gy had no consis-
tent effect in triggering necrotic cell death measured by LDH 
release. These results are in agreement with the results seen 
by Carr et al (18) who only observed a consistent increase in 
LDH release from HNSCC tissue following administration 
of the highest dose of irradiation given (40 Gy). The lack of 
LDH release following irradiation was not due to the fact that 
the tissue had all died during manipulation as the addition of 
lysis reagent to the tissue at the end of the microfluidic culture, 
post-irradiation induced a sharp increase in LDH release 
confirming the viability of the tissue (fig. 6). It is probable 
that the lack of LDH is due to the relatively short timeframe 
over which the tissue was analysed.
Since radioresistance is multifactorial, the use of more than 
one marker to predict HNSCC response is essential (43). In 
comparison to the preliminary study previously conducted by 
Carr et al (18), additional markers were evaluated to measure 
cell death and proliferation in both non-irradiated and irradiated 
samples. One of the impacts of ionising radiation is the formation 
of DNA double-strand breaks (DSBs and the subsequent acti-
vation of the DNA-damage response (DDR) pathway. TUNEL 
has been extensively used to detect DNA fragmentation and 
later stages of apoptosis (44). An increase in the apoptotic rate 
following irradiation on HNSCC cells has been demonstrated 
previously by Feng et al (45) using TUNEL and the effect was 
enhanced when ataxia telangiectasia mutated (ATm), an essen-
tial component of the DNA repair pathway, was inhibited (45,46). 
These results are in agreement with the data in the present study 
which showed that the apoptotic rate of the HNSCC increased 
following irradiation compared to the non-irradiated tissue 
which had a low level of DNA-strand breaks.
figure 6. LDH release levels from tissue following lysis treatment in microfluidic devices. LDH release from an oral cavity floor of mouth primary tumour 
(PT2) following 52-h incubation in three microfluidic devices, subjected to no lysis buffer treatment (n=2) and addition of 10% lysis buffer 6 h prior to the end 
of the experiment (n=1). The absorbance values were assessed in duplicate and standardised per mg of tissue biopsy (5 mg lysis, 7.1 mg control 1 and 5.5 mg 
control 2).
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The phosphorylation of the histone H2AX (γH2AX) is one 
of the early events following the generation of DNA-DSBs and 
is responsible for the recruitment of other molecules in the 
DDR pathway (47). It is thought that γH2AX levels increase 
to a peak expression at 1 h following irradiation and return 
to normal within 24 h (28,48,49). However, a higher reten-
tion level of γH2AX at 24 h following irradiation has been 
observed in a radiosensitive cervical cancer cell line compared 
to a non-sensitive one, where the remaining γH2AX level 
correlated with the surviving fraction of cells determined 
using the clonogenic assay (48), suggesting impaired DNA 
repair, extended DNA repair and radiosensitivity (28,48,49). 
The majority of the tumours in the current study, observed 
at 24 h post-irradiation, had a slight increase in γH2AX 
following irradiation compared with the corresponding 
control tissues, however, this was only significant in one of the 
five tissues (PT2). The increased expression of γH2AX seen 
in PT2 at 24 h post-irradiation may suggest that this tumour 
is more sensitive to irradiation, unfortunately this patient was 
treated with surgery alone so no clinical correlation could be 
made.
The presence of cCK18, as a marker of activation of the 
caspases involved in the apoptotic pathway, has been used 
previously to demonstrate increases in apoptosis in tumour 
tissue following chemotherapy treatments. Conflicting 
results have been reported, however, as the rectal studies 
showed no prognostic value for cCK18 (50,51), but in the 
gastric/gastro-oesophageal cancer patients exposed to neoad-
juvant chemotherapy 43.6% of patients that had tumours 
positive for cCK18, following treatment, had a favourable 
tumour response compared with 23.8% of patients with 
tumours negative for cCK18 expression (52). In the present 
study, a varied response to irradiation in terms of the CK18-LI 
was observed between HNSCC samples from different sub-
sites. for example, the two oral cavity tumours (PT1 and PT2) 
showed minimal response to single-dose irradiation whereas, 
the laryngeal supraglottic tumour (PT3) demonstrated a 
dose-dependent increase following irradiation, reaching signif-
icance compared with the control at 20 Gy; greater numbers 
of tumours would be needed to clarify if these differences are 
sub-site specific. Unexpectedly, two metastatic lymph nodes 
(LN1 and LN2) had a higher CK18-LI (>30%) following 15 Gy 
compared with control tissues which decreased again after 
20 Gy possibly due to increased cellular damage following 
such a high single acute dose (53). The varied responses 
observed among the five tumours confirmed the inter-tumour 
variation on the HNSCC response to irradiation and further 
emphasised the value for individual analysis of tumours to 
determine the patient specific response.
A high pre-treatment proliferation index, measured using 
Ki67, has been shown previously to correlate with reduced 
survival/increased recurrence in patients with HNSCC 
following irradiation (43,54), however, this is the first study to 
use microfluidic culture to analyse the proliferation of tumour 
cells in response to irradiation ex vivo. As hypothesised, the 
expression of Ki-67 in both metastatic lymph nodes in the 
present study followed a trend of dose-dependent reduction 
after irradiation. This was in agreement with other studies 
which have demonstrated a reduction of Ki-67-labelling by 
79% in male wistar rat tissues that were removed from rats 
sacrificed 3 weeks following 10 Gy γ-irradiation (55). In addi-
tion, a reduction of the Ki-67 labelling index was observed 
during the first week following five fractions (1.1 Gy per 
fraction) per week for seven weeks on human normal skin 
biopsies (56). A similar dose-dependent reduction was seen 
in the laryngeal tumour (PT3) except in tissues with 15 Gy 
irradiation. The fact that 15 Gy irradiation appeared to 
have little effect in the laryngeal tumour biopsies, is likely 
to indicate intra-tumour heterogeneity and highlights that 
in future experiments a greater number of replicates need 
to be established for each treatment group. In contrast, no 
effect of irradiation on proliferation was observed in PT1 and 
PT2 samples, who were both treated clinically with surgery, 
suggesting that these tumours might not be responsive to 
irradiation.
In conclusion, although the authors acknowledge the 
microfluidic maintenance of 3-dimensional tumour biopsies 
has limitations, principally in the loss of vasculature, this 
proof-of-concept study shows the potential of the micro-
fluidic-irradiation model and the IHC expression profiles 
to determine the response of an individual's tumour to irra-
diation and provides a system for further investigations of 
various treatment regimens using a methodology applicable 
to all solid tumours. The variation of the tumour responses 
detected between different HNSCC samples and when treating 
samples from the same patient with different irradiation doses 
suggests the existence of both inter- and intra-patient variation 
respectively in terms of response to irradiation in the micro-
fluidic model, highlighting again the need for such a model 
to customise treatment on an individual patient basis prior 
to clinical intervention. The results show that a larger scale 
investigation is the priority, running multiple repeats so that 
the ‘average’ effect can be determined and correlated with the 
corresponding patients' clinical behaviour. A further modifica-
tion to the approach being developed in our group is to use 
precision cut tissue slices in a redesigned tissue device which 
gives improved fluid flow dynamics, increasing the perfusion 
kinetics, ensuring optimal nutrient delivery and waste removal. 
Studies are ongoing comparing these two tissue-bearing 
devices. Prediction of response would bring multiple benefits, 
firstly to the patients in terms of treatment effectiveness and 
quality of life and secondarily to the NHS in terms of cost 
reduction and improved patient care.
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